Mood Med practice Flashcards

1
Q

SSRI MOA

A

decrease action of 5-HT reuptake pump which causes increased serotonin levels in the synapse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

SSRI Dosing

A

Typically QAM can be halved if SE are bad. Metabolized mostly by the liver so caution in hepatic impairement.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

SSRI SE

A

GI (N/D/anorexia) sleep change, headaches, dizziness, decreased libido, anorgasmia, ED, anxiety, increased suicide risk, prolonged QT, weight gain, bleeding, orthostatic hypotension, serotonin syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

SSRI CI

A

allergy to SSRI, use of MAOI within 2 weeks. Fluoxetine must wait 5 weeks.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

SSRI drugs

A

fluvoxamine
fluoxetine
sertraline
Citalopram/Escitalopram
Paroxetine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

SSRI with shortest half life, increased somnolence, DDIs

A

Fluvoxamine special notes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

SSRI with Longest halft life, increased insomnia, DO NOT TAKE w Tamoxifen

A

Fluoxetine special notes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

SSRI with increased GI upset mostly diarrhea, increased insomnia, decreased QT prolongation

A

sertraline special notes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

SSRI with MOST associated with QT prolongation, least impact on liver!

A

Citalopram/Escitalopram special notes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

SSRI with Only one to cause anticholinergic SE, orthostatis hypotension, weight gain, sexual dysfuntion are all increased. DO NOT TAKE w tamoxifen.

A

Paroxetine special notes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

SNRIs MOA

A

Blocks reuptake of 5-HT and NE, increasing their levels in synapse.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

SNRI Dosing

A

takes a few weeks to see full effects. Typically taken QD. Cleared through liver and kidneys.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

SNRI SE

A

N/V/D constipation, dry mouth. Sleep changes, HA, dizziness, anorgasmia, anxiety, suicide, diaphoresis, hypertension, serotonin syndrome.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

SNRI CI

A

allergy to SNRIs; use within 2 weeks of an MAOI, caution if using other serotonergic drugs, caution with angle closure glaucoma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

SNRIs drugs

A

duloxetine
Venlafaxine
Desvenlafaxine
Milnacipran/Levomilnacipran

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Only SNRI with hepatic cytochrome inhibitors which leads to DDIs, LEAST associated w HTN, indicated for chronic pain relief

A

Duloxetine Special notes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

SNRI with higher risk of SE than others. MOST associated w HTN

A

Venlafaxine special notes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

SNRI with synthetic of venlafaxine, Less risk of HTN and other general SE than venlafaxine

A

Desvenlafaxine special notes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

SNRI with Greater effects on NE. most likely to have Psuedo anticholinergic SE (UR, const, dry mouth).

A

Milnacipran/Levomilnacipran special notes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Bupropion MOA

A

acts as dopamine-NE reuptake inhibitor (also antagonizes nicotinic receptors)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

patients with depression that may also want to quit smoking

A

bupropion

22
Q

Weight loss, decreased appetite, Nausea, dry mouth, insomnia, seizures, suicide

A

Bupropion SE

23
Q

CI includes hepatic cytochrome inhibition causes DDIs
allergy
seizure disorder (HIGH RISK OF SEIZURE)
anorexia/bulemia ( causes weight loss and decreased appetite
use within 2 weeks of MAOI

A

Bupropion

24
Q

patients with depression who also have insomnia

A

mirtazapine

25
Q

Mirtazapine MOA

A

antagonizes alpha-2 adrenergic receptors and 5-HT2 and 5-HT3 receptors which causes increased release of serotonin and NE.

26
Q

Dry mouth, increased appetite, weight gain (more than SSRI/SNRI), drowsiness, sedation, sexual dysfunction (less than SSRI).

LOWER HTN RISK
NO HEPATIC CYTOCHROME INHIB.= FEW DDIs

A

Mirtazapine

27
Q

Mirtazapine CI

A

Allergy
MAOI w/i 2 weeks.

28
Q

what are the atypical antidepressants

A

bupropion and mirtazapine

29
Q

Serotonin Modulators MOA

A

blocks the reuptake of 5-HT = increased serotonin
Nefazodone and trazodone also antagonize the 5-HT pump = increased serotonin
Vilazodone and Vortioxetine partially antagonize 5-HT pump = mimic serotonergic effects

30
Q

Serotonin Modulators Dosing

A

QD or BID, Cleared through liver

31
Q

Serotonin Modulators SE

A

nausea, diarrhea, headache, suicide, serotonin syndrome.

32
Q

Serotonin Modulators CI

A

allergy
MAOI use W/I 2 weeks
caution with other serotonergic drugs

33
Q

What are the Serotonin Modulator medications

A

Nefazodone
Trazodone
Vilazodone
Vortioxetine

34
Q

SE: No sexual dysfunction, Less GI. increased Xerostomia, HA, Dizziness, insomnia or drowsiness, agitation, hypotension.
Hepatic Cytochrome enzyme inhibition = MOST DDI RISK OF ALL 5-HT inhib.
BBW = hepatotoxicity.

A

nefazadone

35
Q

SE: nausea, constipation, dry mouth, sedation, fatigue, sexual dysfunction (less than SSRIs or SNRIs.)
Rare: priapism and cardiac arrhythmias

A

Trazodone

36
Q

SE: Nausea, Diarrhea, HA, sexual dysfunction (less than SSRIs or SNRIs)

A

Vilazodone

37
Q

Ketamine/Esketamine MOA

A

opioid and glutamate agonist. NMDA antagonist. mechanism for antidepression is unknown

38
Q

for severe, refractory depression w/o psychosis that is not respondant to ECT. short term use only!

A

Ketamine/Esketamine

39
Q

ketamine/esketamine Dosing

A

ketamine - IV
esketamine - Nasal
rapid effects but effects end in about 2 weeks.

40
Q

abuse potential becuase of euphoric/intoxicated effects
N/V, HA, dizziness, neurotoxicity, hepatotoxicity, bladder toxicity, tachycardia, HTN and abuse/addiction

A

Ketamine/Esketamine

41
Q

Ketamine/Esketamine CI

A

allergy
aneurysmal disease or AV malformation
hx of intracerebral hemorrhage
inability to tolerate increase in BP

42
Q

MAOIs Use

A

usually only for treatment-resistant or atypical depression. selegiline = low dose used for parkinsons

43
Q

MAOI MOA

A

MOAa breaks down serotonin and NE
MOAb works w MOAa to break down dopamine

44
Q

hypotension, GI upset, urinary hesitancy, HA, myoclonic jerks, edema, suicidal ideation, hypertensive crisis w some foods (cheese, beer, tofu, cured meats)

A

MAOI

45
Q

CI includes allergy, CVD, pheochromocytoma (adrenal gland tumor), hepatic/renal impairment, use w serotonergic drugs. LOTS OF DDIs

A

MAOI

46
Q

what medications are the MAOIs

A

Tranylcypromine
Phenelzine
Isocarboxazid
Selegiline

47
Q

Tricyclic antidepressant MOA

A

inhibits reuptake of 5-HT and NE

48
Q

SE includes: Anticholinergic, drowsiness, SD, Diaphoresis, tremor, weight gain, increased appetite, SI, prologned QT (cardiotoxicity), OD risk

A

tricyclic antidepressants

49
Q

this tricyclics antidepressants MOA includes more potent blocking of 5-HT reuptake rather than NE reuptake

A

tertiary amines
amitryptiline
doxepin
imipramine
clomipramine
trimipramine

50
Q

SE includes: Anticholinergic (less than TCAs), drowsiness (more than TCAs), SD, Diaphoresis, tremor, weight gain, increased appetite, SI, prologned QT (cardiotoxicity), OD risk

A

Tetra cyclic antidepressants

51
Q

this tetracyclic antidepressant blocks reuptake of NE and 5-HT

A

Maprotiline

52
Q

this tetracyclic antidepressant blocks reuptake of NE and blocks dopamine receptors

A

Amoxapine